{"id":40366,"date":"2021-04-01T07:41:23","date_gmt":"2021-04-01T07:41:23","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40366"},"modified":"2021-11-21T13:50:06","modified_gmt":"2021-11-21T13:50:06","slug":"dual-eli-lilly-mab-bamlanivimab-and-etesevimab-reduces-hospitalisation-after-single-infusion-results-from-blaze-1-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40366","title":{"rendered":"Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study"},"content":{"rendered":"<p><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-40209\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/03\/CROI-2021-logo-213x300.png\" alt=\"\" width=\"213\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/03\/CROI-2021-logo-213x300.png 213w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/03\/CROI-2021-logo.png 371w\" sizes=\"auto, (max-width: 213px) 100vw, 213px\" \/>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Results from the phase 3 stage of the BLAZE-1 study in 1053 participants with confirmed mild\/moderate COVID-19 reported a 70% reduction in hospitalisation or death by day 29\u00a0 (n=11 vs 36) in those randomised to the active monoclonal antibodies (mAbs) vs placebo (p=0.0004). [1]<\/strong><\/p>\n<p>The two neutralising mAbs in development by Eli-Lilly (2800mg bamlanivimab+2800mg etesevimab) were given together as a single infusion within three days of diagnosis.<\/p>\n<p>Deaths were significantly reduced (n=0 vs 10) and symptoms resolved faster in the active arm. Median drop in viral load at day 7: difference \u20131.20 log (95%CI: \u20131.46 to \u20130.94), p&lt;0.00000001).<\/p>\n<p>Similar rates of adverse events were reported for the combined treatment vs placebo groups (13.3 % vs 11.6%).<\/p>\n<p>Results from the phase 2 dose-finding stage of this study were reported in the NEJM in October. [2]<\/p>\n<p>References<\/p>\n<ol>\n<li>Dougan M et al. Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. CROI 2021, virtual. Late breaking oral abstract 122.<br \/>\n<a title=\"https:\/\/www.croiconference.org\/abstract\/bamlanivimabetesevimab-for-treatment-of-covid-19-in-high-risk-ambulatory-patients\/\" href=\"https:\/\/www.croiconference.org\/abstract\/bamlanivimabetesevimab-for-treatment-of-covid-19-in-high-risk-ambulatory-patients\/\">https:\/\/www.croiconference.org\/abstract\/bamlanivimabetesevimab-for-treatment-of-covid-19-in-high-risk-ambulatory-patients\/<\/a>(abstract and webcast)<\/li>\n<li>Two different dual antibody treatments each reduce SARS-CoV-2 viral load by &gt;0.5 log. HTB (22 January 2021).<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/39718\">https:\/\/i-base.info\/htb\/39718<\/a><\/li>\n<\/ol>\n<p><em>This report was first published on 19 March 2021.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Results from the phase 3 stage of the BLAZE-1 study in 1053 participants with confirmed mild\/moderate COVID-19 reported a 70% reduction in hospitalisation or death by day 29\u00a0 (n=11 vs 36) in those randomised to the &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,283,278],"tags":[307],"class_list":["post-40366","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-covid-19-investigational-drugs","category-covid-19","tag-croi-2021-virtual"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40366"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40366\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}